Loading...
Loading...
ADAG| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 9,160.9K |
| Operating I/L | -9,160.9K |
| Other Income/Expense | 655.8K |
| Interest Income | 1,976.6K |
| Pretax | -8,505.2K |
| Income Tax Expense | 0.7K |
| Net Income/Loss | -8,505.9K |
Adagene Inc. is a clinical stage biopharmaceutical company specializing in the research, development, and production of monoclonal antibody drugs for the treatment of various cancers. The company's product candidates include a range of monoclonal antibodies such as ADG106, ADG126, ADG116, ADG104, ADG125, ADG206, ADG153, ADG138, and ADG152, which are in various stages of clinical development for the treatment of advanced solid tumors, non-Hodgkin's lymphoma, metastatic solid tumors, and off-tumor toxicities. These innovative drug candidates form the core of Adagene's revenue generation and future growth strategy.
